Multiple Myeloma
Dextech Medical AB focuses on multiple myeloma research, with interest in treatment options for relapsed/refractory disease and the clinical evaluation of therapies designed for this hematologic malignancy.
- Relapsed/refractory multiple myeloma
- Hematologic oncology
- Anticancer therapeutics
The sponsor’s research activity is centered on clinical investigation in oncology, specifically within the therapeutic area of plasma cell disorders.
Bone-Targeted Therapeutics
Its clinical research also reflects interest in bone-associated treatment strategies, aligning with therapeutic development for malignancies that involve the skeletal system and the bone microenvironment.
- Bone-directed therapy
- Osteolytic disease
- Skeletal involvement in cancer
This area links the sponsor’s work to medical needs where control of bone-related complications is relevant in cancer care.
Oncology Drug Development
Dextech Medical AB is involved in the clinical assessment of anticancer agents intended for use in malignant hematology, with emphasis on therapies under evaluation for safety and tolerability in patients with advanced disease.
- Clinical oncology
- Therapeutic safety
- Tolerability assessment
The sponsor’s portfolio indicates a concentrated interest in advancing treatment options for cancer patients with limited existing therapeutic choices.
